Company: AVCRF
Filing Date: 2025-06-16
Form Type: 20-F
Source: 0001641172-25-015266
Chunk: 77

Company: Avricore Health Inc.
Filing Date: 2025-06-16
Form: 20-F
Item: Item 19
Chunk 77
---
,889 1,062 9,736 12,000 12,000

Avricore
Health Inc.

Notes
to the Consolidated Financial Statements

For
the years ended December 31, 2024, 2023 and 2022

(Expressed
in Canadian Dollars)

  EQUIPMENT  
 ─────────────

SCHEDULE OF EQUIPMENT

  Cost                                                        
  Balance,                                         1,298,703  
  Additions                                        1,021,572  
  Balance,                                         2,320,275  
  Cost, beginning balance                          2,320,275  
  Additions                                          181,094  
  Impairment                                       ( 772,174  
  Assets                                           ( 162,686  
  Balance,                                         1,566,509  
  Cost, ending balance                             1,566,509  
  Accumulated                                                 
  Balance,                                           190,712  
  Amortization                                       411,568  
  Balance,                                           602,280  
  Accumulated amortization, beginning balance        602,280  
  Amortization                                       438,441  
  Assets                                           ( 130,653  
  Balance,                                           910,068  
  Accumulated amortization, ending balance           910,068  
  Carrying                                                    
  As                                               1,717,995  
  Beginning balance                                1,717,995  
  As                                                 656,441  
  Ending balance                                     656,441  

Equipment
is comprised primarily of system analyzers and system hardware leased to earn revenues. Amortization of equipment included in cost of
sales was $ 435,304 409,221 3,137 2,347 32,033 Nil

During
the year, management determined that the agreement with the Company’s major customer would not be renewed and expire on March 31,
2025. The loss of this major customer was expected to significantly impact the Company’s revenue and financial position in the
near term. As a consequence, the Company performed an impairment test. The Company recognized and determined the recoverable amount to
be $ 656,441 50 772,174 Nil 100

Avricore
Health Inc.

Notes
to the Consolidated Financial Statements

For
the years ended December 31, 2024, 2023 and 2022

(Expressed
in Canadian Dollars)

  INTANGIBLE  
  ASSETS